PUMA BIOTECHNOLOGY INC (PBYI)
Puma Biotechnology Inc. (PBYI) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. Founded with the goal of creating innovative treatments, the company is known for its research and development efforts in oncology, particularly in the area of breast cancer. Puma Biotechnology's flagship product, neratinib, is an oral tyrosine kinase inhibitor approved for certain breast cancer indications. The company emphasizes advancing oncology therapies to improve patient outcomes through scientific innovation.
Company News
Er-Kim, an international pharmaceutical company, has signed an agreement with Puma Biotechnology to commercialize NERLYNX, a targeted therapy for early-stage HER2-positive breast cancer, in select countries in Eastern Europe and Central Asia.
Puma Biotechnology's Chief Commercial Officer, Jeffrey Jerome Ludwig, sold 2,598 shares of the company's common stock for over $9,600. The sale was part of a pre-arranged trading plan, and Ludwig's direct ownership in the company now stands at 118,388 shares.
Ratings for Puma Biotechnology (NASDAQ:PBYI) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. This current average has not changed from the previous average price target. Interpreting Analyst Ratings: A Closer Look The standing of Puma Biotechnology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintains Buy $7.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
The company's CEO bought $2.5 million worth of company stock.
